Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver

Related Experiment Video

Updated: Jun 7, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Alexandra Rogue1, Catherine Spire, Manuel Brun

  • 1UMR INSERM U991, Faculté des Sciences Pharmaceutiques et Biologiques, 35043 Rennes, France.

PPAR Research
|October 29, 2010
PubMed

Insights

Thiazolidinediones, used to treat type 2 diabetes, can cause liver damage through unclear mechanisms. Individual responses vary, with some patients experiencing adverse effects while others do not.

Area of Science:

  • Pharmacology
  • Hepatology
  • Endocrinology

Background:

  • Thiazolidinediones are Peroxisome Proliferator Activated Receptor γ (PPARγ) agonists.
  • They are used to reduce insulin resistance in type 2 diabetes.
  • Despite preclinical safety, some patients experience drug-induced liver injury.

Purpose of the Study:

  • To review the mechanisms of thiazolidinedione-induced hepatotoxicity.
  • To analyze data from in vivo and in vitro experimental models.
  • To investigate PPARγ-dependent and independent effects in the liver.

Main Methods:

  • Review of existing studies using PCR analysis and microarray technology.
  • Analysis of data from various in vivo and in vitro experimental models.
  • Examination of primary human hepatocyte responses to troglitazone.

Main Results:

  • PPARγ agonists have both PPARγ-dependent and independent effects in the liver.
  • Effects vary based on the specific agonist and experimental conditions.
  • Hepatotoxicity is more pronounced in obese and diabetic liver models.
  • Significant interindividual variability exists in human hepatocyte response to troglitazone.

Conclusions:

  • The precise mechanisms of thiazolidinedione hepatotoxicity remain unclear.
  • Individual genetic variability likely contributes to differential susceptibility to liver injury.
  • Further research is needed to understand and predict patient responses.

Related Concept Videos

Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...